Kite, a Gilead Company (NASDAQ: GILD), today announced the completion of the previously announced transaction to acquire Tmunity Therapeutics (Tmunity), a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies. The acquisition of Tmunity complements Kite’s existing .
Alliance for Cancer Gene Therapy announces Summit 2021 be there when the next breakthroughs happens eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
A scientific team led by Brian Brown, PhD, Professor of Genetics and Genomic Sciences and Associate Director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai (New York, New York), has been awarded $500,000 from Alliance for Cancer Gene Therapy to advance a promising immunotherapy approach to fight lung cancer and other solid tumor cancers.
E-Mail
IMAGE: Brian Brown, PhD, professor of Genetics and Genomic Sciences and Associate Director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai (New York, New York), has. view more
Credit: Mount Sinai
A scientific team led by Brian Brown, PhD, Professor of Genetics and Genomic Sciences and Associate Director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai (New York, New York), has been awarded $500,000 from Alliance for Cancer Gene Therapy (ACGT) to advance a promising immunotherapy approach to fight lung cancer and other solid tumor cancers.
Despite some amazing successes, not all patients respond to current immunotherapies. Dr. Brown notes that one cell type that appears to be responsible for poor responses to immunotherapy against solid tumors is called a macrophage. As part of the natural immune system, macrophages typically protect patients from infections, but tumors can reprogram mac